Use of IV immunoglobulin was associated with a significantly reduced ICU length of stay in immunocompromised patients with respiratory viral infections.
In conclusion, we consider that the available data indicate that IVIg is not a lost cause for the therapy of MS 15,16, and that clinical trials are therefore warranted to determine if a ...
With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...
With many patients, a critical element of treatment is infusion of intravenous immune globulin (IVIG). Congress should ensure that comparative effectiveness research does not allow for cost ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...